|
Dr. Browne has over twenty years of experience in the pharmaceutical industry across multiple disciplines including Research & Development, Operations, and Business Development. Prior to joining Pharmacopeia, Dr. Browne was the Chief Operating Officer at Iconix Pharmaceuticals, Inc., a leading chemogenomics company, where he led the research, development and informatics operations and launched Iconix's first product, DrugMatrix®. Before joining Iconix Dr. Browne held several positions at Berlex/Schering AG, including Corporate Vice President, Berlex Laboratories, Inc. and President of Schering Berlin Venture Corporation. At Berlex Biosciences he rebuilt the drug discovery operation and championed a number of important pharma-biotech deals for Berlex, including a combinatorial chemistry collaboration with Pharmacopeia. Before Berlex, he was with Ciba-Geigy, where he discovered Fadrozole, the first marketed non-steroidal aromatase inhibitor for the treatment of estrogen-dependent breast cancer. He also managed cardiovascular research at Ciba-Geigy Ltd., in Basle, where one of the group's achievements was the discovery of Diovan®, the second angiotensin II antagonist ever to be marketed. Over his career, Dr. Browne has authored numerous publications and patents covering a broad range of therapeutic areas including CNS, cardiovascular disease, inflammation and cancer. Dr. Browne received his B.Sc. at Strathclyde University, in Glasgow, Scotland. After receiving his Ph.D. from the University of Michigan, he was a National Institutes of Health postdoctoral fellow at Harvard with the Nobel laureate Professor R. B. Woodward. | 